Atezolizumab (Tecentriq) received a supplemental FDA approval for efficacy on July 30, 2020. This approval, designated BLA 761034 S-28, was granted to sponsor Genentech Inc. for an efficacy-related update to the drug's label.
Background
Atezolizumab, also known by its brand name Tecentriq, is a therapeutic agent that received a supplemental approval for efficacy. Supplemental applications typically involve updates or expansions to an already approved drug's label, often based on new clinical data. This particular approval was categorized under 'Efficacy,' indicating that new data supported a benefit in a specific area of treatment.
What this means
The supplemental FDA approval for Atezolizumab (Tecentriq) on July 30, 2020, signifies that the agency has reviewed new data supporting an efficacy claim for the drug. While the specific details of the indication or patient population for this efficacy update are not provided in the summary, such approvals are crucial for expanding the utility of existing treatments. For clinicians, this means a potential new use or an updated understanding of the drug's benefits in a specific context. Researchers and patient advocates can note this as an expansion of the drug's therapeutic profile, prompting further investigation into its implications for patient care. This type of approval reflects ongoing efforts to refine and optimize treatment strategies based on evolving scientific evidence.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA). The approval for supplemental application BLA 761034 S-28 for Tecentriq (atezolizumab) was documented on July 30, 2020, on accessdata.fda.gov.